Our top pick for
Curis, Inc is a biotechnology business based in the US. Curis shares (CRIS) are listed on the NASDAQ and all prices are listed in US Dollars. Curis employs 28 staff and has a trailing 12-month revenue of around USD$11.1 million.
|52-week range||USD$0.62 - USD$13.44|
|50-day moving average||USD$10.4579|
|200-day moving average||USD$4.6584|
|Wall St. target price||USD$15.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.913|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$11.1 million|
|Gross profit TTM||USD$-12,801,000|
|Return on assets TTM||-36.89%|
|Return on equity TTM||0%|
|Market capitalisation||USD$894.7 million|
TTM: trailing 12 months
There are currently 2.1 million Curis shares held short by investors – that's known as Curis's "short interest". This figure is 63.5% up from 1.3 million last month.
There are a few different ways that this level of interest in shorting Curis shares can be evaluated.
Curis's "short interest ratio" (SIR) is the quantity of Curis shares currently shorted divided by the average quantity of Curis shares traded daily (recently around 2.2 million). Curis's SIR currently stands at 0.94. In other words for every 100,000 Curis shares traded daily on the market, roughly 940 shares are currently held short.
However Curis's short interest can also be evaluated against the total number of Curis shares, or, against the total number of tradable Curis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Curis's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Curis shares in existence, roughly 20 shares are currently held short) or 0.0254% of the tradable shares (for every 100,000 tradable Curis shares, roughly 25 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Curis.
Find out more about how you can short Curis stock.
We're not expecting Curis to pay a dividend over the next 12 months.
Curis's shares were split on a 1:5 basis on 30 May 2018. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Curis shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Curis shares which in turn could have impacted Curis's share price.
Over the last 12 months, Curis's shares have ranged in value from as little as $0.62 up to $13.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Curis's is 3.0662. This would suggest that Curis's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation; and Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors. The company's products in pipeline include CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and DarwinHealth, Inc. to characterize biomarkers and tumor subtype alignments to identify therapeutic opportunities. The company was founded in 2000 and is headquartered in Lexington, Massachusetts.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.